Derek J Sloan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6170483/publications.pdf

Version: 2024-02-01

57	1,232	18	32
papers	citations	h-index	g-index
61	61	61	2068
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	High Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis. Microbiology Spectrum, 2022, , e0210021.	1.2	7
2	Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease. International Journal of Tuberculosis and Lung Disease, 2022, 26, 276-278.	0.6	2
3	Detection and Quantification of Viable Mycobacterium tuberculosis Bacilli in Saline-Processed Stool Samples by Tuberculosis Molecular Bacterial Load Assay: a Potential Alternative for Processing Stool. Microbiology Spectrum, 2022, , e0027422.	1.2	0
4	Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. Clinical Infectious Diseases, 2021, 73, e3365-e3373.	2.9	9
5	MicroRNAâ€122 and cytokeratinâ€18 have potential as a biomarkers of drugâ€induced liver injury in European and African patients on treatment for mycobacterial infection. British Journal of Clinical Pharmacology, 2021, 87, 3206-3217.	1.1	14
6	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics, 2021, 60, 685-710.	1.6	39
7	Protocol for an interdisciplinary cross-sectional study investigating the social, biological and community-level drivers of antimicrobial resistance (AMR): Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA). BMJ Open, 2021, 11, e041418.	0.8	24
8	Pan-Resistome Characterization of Uropathogenic Escherichia coli and Klebsiella pneumoniae Strains Circulating in Uganda and Kenya, Isolated from 2017–2018. Antibiotics, 2021, 10, 1547.	1.5	11
9	How mechanistic in silico modelling can improve our understanding of TB disease and treatment. International Journal of Tuberculosis and Lung Disease, 2020, 24, 1145-1150.	0.6	5
10	Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa218.	0.4	11
11	STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLoS Medicine, 2020, 17, e1003344.	3.9	17
12	All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. ERJ Open Research, 2020, 6, 00315-2020.	1.1	16
13	Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 1089-1098.	4.6	10
14	TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care. International Journal of Tuberculosis and Lung Disease, 2020, 24, 131-132.	0.6	0
15	Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials, 2020, 21, 181.	0.7	14
16	Accuracy and consequences of usingtrial-of-antibiotics for TB diagnosis (ACT-TB study): protocol for a randomised controlled clinical trial. BMJ Open, 2020, 10, e033999.	0.8	1
17	Molecular Detection of Mycobacterium tuberculosis in Oral Mucosa from Patients with Presumptive Tuberculosis. Journal of Clinical Medicine, 2020, 9, 4124.	1.0	16
18	A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA). Journal of Visualized Experiments, 2020, , .	0.2	8

#	Article	IF	Citations
19	Characterization of DNA methylation in Malawian <i>Mycobacterium tuberculosis</i> clinical isolates. PeerJ, 2020, 8, e10432.	0.9	4
20	Linezolid for drug-resistant pulmonary tuberculosis. The Cochrane Library, 2019, 3, CD012836.	1.5	52
21	An Undulating Fever. , 2019, , 54-58.		0
22	Popping Problems. , 2019, , 242-247.		0
23	<i>NAT2</i> variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 293-305.	0.6	24
24	Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ Open, 2019, 9, e030212.	0.8	3
25	PrimeStore MTM and OMNIgene Sputum for the Preservation of Sputum for Xpert MTB/RIF Testing in Nigeria. Journal of Clinical Medicine, 2019, 8, 2146.	1.0	7
26	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2018, 73, 1755-1762.	1.3	32
27	CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. Systematic Reviews, 2018, 7, 204.	2.5	10
28	Effect of the duration of antimicrobial exposure on the development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis. Systematic Reviews, 2018, 7, 246.	2.5	2
29	Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic Reviews, 2018, 7, 141.	2.5	5
30	The occurrence and frequency of genomic mutations that mediate Isoniazid and Rifampicin resistance in Mycobacterium tuberculosis isolates from untreated pulmonary Tuberculosis cases in urban Blantyre, Malawi. Malawi Medical Journal, 2018, 30, 1.	0.2	5
31	Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis. Tuberculosis, 2018, 112, 79-82.	0.8	7
32	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	28
33	TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi. BMC Infectious Diseases, 2017, 17, 259.	1.3	8
34	Equitable tuberculosis care in the North West of England: analysis of tuberculosis cohort review data. International Journal of Tuberculosis and Lung Disease, 2016, 20, 778-785.	0.6	1
35	Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB. Tuberculosis, 2016, 98, 110-115.	0.8	25
36	Health professionals' experiences of tuberculosis cohort audit in the North West of England: a qualitative study. BMJ Open, 2016, 6, e010536.	0.8	4

#	Article	IF	CITATIONS
37	Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 163-172.	0.7	37
38	First experience of effectiveness and safety of bedaquiline for 18â€months within an optimised regimen for XDR-TB. European Respiratory Journal, 2016, 47, 1581-1584.	3.1	34
39	Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study. PLoS ONE, 2016, 11, e0165734.	1.1	3
40	Tuberculosis in the time of Ebola: obstacles and opportunities. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1269-1269.	0.6	3
41	The role of delamanid in the treatment of drug-resistant tuberculosis. Therapeutics and Clinical Risk Management, 2015, 11, 779.	0.9	57
42	Kinetics of Mycobacterium tuberculosis-specific IFN- \hat{l}^3 responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis. Tuberculosis, 2015, 95, 463-469.	0.8	3
43	Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2015, 61, 1-8.	2.9	72
44	Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2015, 19, 904-911.	0.6	17
45	Cryptococcal meningitis: epidemiology and therapeutic options. Clinical Epidemiology, 2014, 6, 169.	1.5	207
46	A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi. PLoS ONE, 2014, 9, e110285.	1.1	56
47	Evidence of improving antiretroviral therapy treatment delays: an analysis of eight years of programmatic outcomes in Blantyre, Malawi. BMC Public Health, 2013, 13, 490.	1.2	9
48	Evaluation of Xpert MTB/RIF for Detection of Tuberculosis from Blood Samples of HIV-Infected Adults Confirms Mycobacterium tuberculosis Bacteremia as an Indicator of Poor Prognosis. Journal of Clinical Microbiology, 2013, 51, 2311-2316.	1.8	50
49	A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi. PLoS ONE, 2013, 8, e67311.	1.1	62
50	New Drugs and Treatment Regimens. Current Respiratory Medicine Reviews, 2013, 9, 200-210.	0.1	40
51	Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings. Journal of Clinical Microbiology, 2012, 50, 2315-2320.	1.8	21
52	Treatment of cryptococcal meningitis in resource limited settings. Current Opinion in Infectious Diseases, 2009, 22, 455-463.	1.3	47
53	Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. Journal of Medical Case Reports, 2008, 2, 370.	0.4	16
54	Cytomegalovirus Retinitis in the Absence of HIV or Immunosuppression. European Journal of Ophthalmology, 2008, 18, 813-815.	0.7	34

#	Article	IF	CITATIONS
55	Healthcareâ€seeking behaviour and use of traditional healers after snakebite in Hlabisa subâ€district, KwaZulu Natal. Tropical Medicine and International Health, 2007, 12, 1386-1390.	1.0	38
56	Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort. Wellcome Open Research, 0, 6, 19.	0.9	0
57	Linezolid for drug-resistant tuberculosis. The Cochrane Library, 0, , .	1.5	3